Status:
COMPLETED
Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Erythropoietin (EPO) is a hormone produced in the kidney. Its function is to stimulate the production of red cells in the bone marrow. The purpose of this research study is to demonstrate that the adm...
Detailed Description
In this study the amount of drug and frequency of dosing is under investigation. Erythropoietin (EPO) will be given by subcutaneous injection (a small needle prick placed underneath the skin). The max...
Eligibility Criteria
Inclusion
- Critically ill patient admitted to the ICU
- Patient is anemic when entering the study (hemoglobin \</= 12.0 g/dL)
Exclusion
- Patients with a history of blood clots (deep vein thrombosis)
- Patients with acute ischemic cardiac disease
- Patients receiving hemodialysis or peritoneal dialysis
- Patients admitted to the ICU because of acute GI bleeding
- Patients who are planned to be discharged from the ICU within 48 hours of entering the study
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
1460 Patients enrolled
Trial Details
Trial ID
NCT00091910
Start Date
September 1 2003
End Date
June 1 2006
Last Update
June 8 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.